Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVB-081 subretinal gene therapy study in adults with Usher syndrome type 1B retinitis pigmentosa
2024-518489-29-00Phase 2Authorised
- Sponsor
- AAVantgarde Bio
- Start
- Nov 2024
- Modality
- Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of AAVB-081 in Usher syndrome type 1B (USH1B) and retinitis pigmentosa (RP), sponsored by AAVantgarde Bio. Primary endpoints: Incidence and severity of adverse events and Incidence and nature of dose-limiting toxicities. Planned start Nov 2024; status: authorised.
02
Drugs
AAVB-081
03
Conditions
Usher syndrome type 1B (USH1B)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2024-518489-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518489-29-00.